🔎 Trials Near Me

Почетна › Немалоклетни карцином плућа › Nebraska

Kliničke studije za Немалоклетни карцином плућа u državi Nebraska

40 studija za Немалоклетни карцином плућа traži učesnike na lokacijama u državi Nebraska.

Gradovi u državi Nebraska

Zvanični tekst studije (na engleskom)

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Fremont, Fremont
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Grand Island, Grand Island
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Regional, Grand Island
  • и још 5
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06758401

A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

  • NHO Revive Research Institute LLC ( Site 0118), Lincoln
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07554339

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • Nebraska Medicine-Bellevue, Bellevue
  • Fred and Pamela Buffett Cancer Center - Kearney, Kearney
  • CHI Health Good Samaritan, Kearney
  • и још 5
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT04267848

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

  • Nebraska Hematology-Oncology - Revive Research Institute LLC, Lincoln
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06472245

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

  • Local Institution - 0402, Omaha
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT07680790

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

  • Research Site, Lincoln
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT07291037

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

  • NHO Revive Research Institute, LLC ( Site 3218), Lincoln
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT07513376

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

  • Nebraska Cancer Specialists - Grand Island, Grand Island
  • Nebraska Cancer Specialists, Omaha
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT04198766

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  • Nebraska Medicine-Bellevue Medical Center, Bellevue
  • Nebraska Medicine, Omaha
  • Nebraska Medicine - Village Pointe, Omaha
  • и још 1
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07144280

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  • NHO Revive Research Institute, Lincoln
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06793215

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  • CHI Health Good Samaritan, Kearney
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06418204

Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors

  • Nebraska Cancer Specialists, Omaha
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07660055

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

  • Nebraska Hematology-Oncology, Lincoln
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07288177

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

  • Mary Lanning Healthcare (MLH) - Morrison Cancer Center (MCC), Hastings
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT06712316

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  • Local Institution - 007-590D, Grand Island
  • Local Institution - 007-590A, Omaha
  • Local Institution - 007-590B, Omaha
  • и још 2
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT04613596

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

  • USA14-0, Lincoln
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06953089

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

  • Research Site, Lincoln
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06692738

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

  • Research Site, Grand Island
  • Research Site, Omaha
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT06357533

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • Nebraska Cancer Specialists, Grand Island
  • Oncology Hematology West PC, Omaha
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT07680764

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

  • Nebraska Hematology-Oncology /ID# 272970, Lincoln
  • Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271527, Omaha
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT06568939

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

  • Research Site, Omaha
Тражи се учесникФаза 2
Узраст од 18 до 95 · Оба пола · Ажурирано 21. 10. 2026. · NCT05061550

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

  • Nebraska Cancer Specialist, Grand Island
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 19. 10. 2026. · NCT06162221

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

  • Nebraska Medicine- Bellevue Medical Center, Bellevue
  • Cancer Partners of Nebraska, Lincoln
  • Nebraska Medicine, Omaha
  • и још 2
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2026. · NCT07489066

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • NHO Revive Research Institute, LLC, Lincoln
  • NHO Support Center, Lincoln
  • Cancer Partners of Nebraska, Lincoln
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2026. · NCT07222566

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

  • Nho - Revive Research Institute /ID# 277569, Lincoln
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 5. 10. 2026. · NCT07155187

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

  • Exelixis Clinical Site #2, Omaha
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 1. 10. 2026. · NCT05176483

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

  • Nebraska Cancer Specialists, Omaha
  • XCancer, Omaha
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 1. 10. 2026. · NCT07189871

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

  • Research Site, Lincoln
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 25. 9. 2026. · NCT06868277

Pan-tumor MRD Study

  • Cancer Partners of Nebraska, Lincoln
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 24. 9. 2026. · NCT06605404

A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer

  • University of Nebraska Medical Center, Omaha
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 27. 7. 2026. · NCT05242965

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

  • Nebraska Medicine-Bellevue, Bellevue
  • Nebraska Medicine-Village Pointe, Omaha
  • University of Nebraska Medical Center, Omaha
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 14. 7. 2026. · NCT06686771

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

  • University of Nebraska Medical Center, Omaha
Тражи се учесникФаза 2
Узраст од 18 до 70 · Оба пола · Ажурирано 26. 6. 2026. · NCT04614103

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

  • Nebraska Cancer Specialists - Omaha - Wright Street /ID# 247399, Omaha
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 23. 6. 2026. · NCT05005403

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

  • Nebraska Cancer Specialists (Midwest Cancer Center - Legacy), Omaha
  • XCancer Omaha / Urology Cancer Center, Omaha
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 11. 6. 2026. · NCT05283330

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

  • University of Nebraska Medical Center, Omaha
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 5. 5. 2026. · NCT04317534

Repositioning Immunotherapy in VetArans With Lung Cancer

  • Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE, Omaha
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 2. 3. 2026. · NCT06275360

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

  • Nebraska Cancer Specialists, Omaha
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 18. 2. 2026. · NCT07030257

GEMINI-NSCLC: NSCLC Biomarker Study

  • Nebraska Cancer Specialists, Omaha
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 5. 2. 2026. · NCT05236114

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Omaha
Тражи се учесникОпсервациона студија
Сви узрасти · Оба пола · Ажурирано 28. 10. 2025. · NCT03452774

A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer

  • Nebraska Cancer Specialists, Omaha
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 23. 4. 2025. · NCT06046495

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.